Quantcast
Last updated on April 23, 2014 at 11:05 EDT

Latest Biomarker discovery Stories

2014-04-08 12:30:37

-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat(TM) prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States. An initial pilot study to be launched in April will examine 300 patient samples and is...

2014-01-29 20:23:47

DUBLIN, January 30, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/blxrzk/biomarkers ) has announced the addition of a new report "Biomarkers - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/blxrzk/biomarkers ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report follows the broad definition of a biomarker as a characteristic that can be objectively...

2014-01-13 04:20:54

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ -- - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies - Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine - Automated biofluid-based molecular diagnostics have significant potential to...

2013-11-19 23:25:01

The Quarterly Online Seminar Series Starts with Advanced Genomics in Clinical and Translational Research, November 20, 2013. Yorba Linda, CA (PRWEB) November 19, 2013 Life Technologies has developed a new online seminar series to help researchers and clinicians stay updated on the most recent developments in science. These quarterly events will focus on topics in translational research and clinical diagnostics including pharmacogenomics, infectious disease, advances in cancer research,...

2013-11-19 08:27:59

SAN DIEGO, Nov. 19, 2013 /PRNewswire/ -- Applied Proteomics Inc. (API), the leading developer of protein-based molecular diagnostics, announces the appointment of Premal S. Shah, Ph.D., as vice president of business development. Dr. Shah was previously director of business development at Genomic Health, where he was responsible for driving go-to-market strategies and establishing key collaborations with pharmaceutical companies for joint biomarker discovery ventures. "API is...

2013-09-30 08:29:38

NEW YORK, Sept. 30, 2013 /PRNewswire/ -- Exosome Diagnostics today announced that it has selected Cedars-Sinai Medical Center to participate in an early technology access program for use of exosome RNA biofluid extraction kits for biomarker discovery in neo-natal and other disease settings. "The ability to monitor patients, particularly extreme premature infants, using real-time biofluid based genetics tests, may provide critical information which is currently unavailable, said...

2013-09-19 08:28:42

NEW YORK, Sept. 19, 2013 /PRNewswire/ -- Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit. Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease...

2013-07-26 12:25:30

DUBLIN, July 26, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kwrwjt/biomarkers) has announced the addition of a new report "Biomarkers - Technologies, Markets and Companies [http://www.researchandmarkets.com/research/kwrwjt/biomarkers ]" to their offering. This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or...

2013-07-23 16:24:12

GERMANTOWN, Maryland, and HILDEN, Germany, July 23, 2013 /PRNewswire/ -- - Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies - Developing Exosome Diagnostics technology for use with QIAGEN's nucleic acid-targeted consumables and automation - with initial product launches targeted in 2014 -...

2013-07-23 16:24:10

-- Molecular testing of biofluids promises unprecedented access to gene mutations, real-time gene expression signatures and expression levels without costly, invasive tissue biopsies NEW YORK, July 23, 2013 /PRNewswire/ -- Exosome Diagnostics and QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership to develop and commercialize high-performance, co-branded kit products for the capture and processing of RNA and DNA from biofluid exosomes and other...